Cassava Sciences Inc vs Paycom Software Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Paycom Software Inc trades at $211 (market cap $9.62B). The key difference: Paycom Software Inc is far larger — about 201.5× Cassava Sciences Inc's market cap, and Paycom Software Inc pays a 0.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PAYC | |
|---|---|---|
Market Cap | $47.75M | $9.62B |
Sector | Health | Technology |
52-Week High | $4.64 | $233.89 |
52-Week Low | $0.87 | $113.59 |
Enterprise Value | -$34.93M | $10.41B |
Dividend Yield | — | 0.7% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Paycom Software (PAYC) trades at $214.94, down 0.48% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong fundamentals, including a 22.78% net income margin and consistent earnings beats, most recently with Q2 2026 EPS of $2.78 versus $2.38 expected. Recent news highlights AI-driven demand and raised 2026 guidance, fueling positive sentiment.
Outlook remains favorable due to robust profitability and growth initiatives, though risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting modest upside potential from current levels amid balanced buy/hold ratings.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →